ST Humanwell announced that its controlling subsidiary Wuhan Jiulong Humanwell Pharmaceutical has received the Drug Registration Certificate for Phloroglucinol Orally Disintegrating Tablets issued by the National Medical Products Administration. The specification is 80 milligrams, the registration classification is chemical drug category 3, and the drug approval number is valid until September 1, 2031. The drug is used to treat acute spasmodic pain caused by digestive system and biliary tract dysfunction, acute spasmodic pain of the urethra, bladder and kidney, and gynecological spasmodic pain. Jiulong Humanwell entrusted Nanjing Haina Pharmaceutical to produce the product, submitted the marketing authorization application in December 2024, and has invested a cumulative total of approximately 8 million yuan. The company stated that this approval marks that Jiulong Humanwell is qualified to sell in the domestic market and further enriches its product line, but future sales are subject to uncertainty due to industry policies and market conditions.
Humanwell Healthcare Group Co LtdControlling subsidiary Wuhan Jiulong Humanwell received NMPA Drug Registration Certificate for Phloroglucinol Orally Disintegrating Tablets, qualifying it to sell in the domestic market and enriching its product line.
Named only as the entrusted manufacturer (contract manufacturer) for the product; no independent financial or commercial impact stated.
